Study drug for advanced cancers with KRAS G12D mutation
Treatments studied
Part of Cancer clinical trials.
This Phase 1 trial tests ASP3082 in adults with advanced or metastatic solid tumors that have a KRAS G12D mutation. It may help people whose standard targeted treatments are no longer working, or who cannot receive standard approved therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic solid cancer that cannot be removed by surgery, and it has a KRAS G12D mutation
- You have had prior standard treatment (or you cannot receive approved standard treatments) and the study doctor sees little/no further benefit from continuing prior targeted therapy
- You can provide tumor tissue (a biopsy or stored tumor slides) collected before the study drug starts, and possibly another biopsy during treatment
- Imaging shows at least one measurable tumor spot, and you are well enough to do daily activities (ECOG 0–2 depending on the trial part)
- Your last cancer treatment was stopped at least 21 days (or 5 “half-lives,” whichever is shorter) before starting, and any side effects are mostly improved
- If you recently had radiation, it must be at least 14 days ago and you must have recovered from radiation side effects
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (ASP5834) for people with advanced solid tumors that have changes in the KRAS gene. The study looks for a safe and effective dose, and may help you if your standard treatments have stopped working.
This trial tests a new drug called PT0253 for people with advanced solid tumors that have a specific genetic change (KRAS G12D). The drug aims to target and slow down the growth of cancer cells with this mutation.
This trial tests D3S-001 (alone or with other treatments) in people with advanced solid cancers that have a KRAS G12C mutation. It’s mainly aimed at early safety and learning whether the treatment can shrink or control tumors.
This study tests an experimental drug called VS-7375 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth.
This trial tests a new pill, KST-6051, for people with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called a KRAS mutation. The goal is to see if the drug can shrink or control the cancer, and to find the best dose.
This trial tests a new drug called KQB548 for people with certain advanced cancers (pancreatic, colorectal, or lung) that have a specific genetic change called KRAS G12D. It's for those whose cancer has continued to grow despite previous treatments.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.